Pharmaceutical

Filter

Current filters:

None

Popular Filters

1 to 25 of 7222 results

Pharma CEO salaries and performance pay “is not politicians’ business,” says Polyplus chief

Pharma CEO salaries and performance pay “is not politicians’ business,” says Polyplus chief

04-03-2015

The political establishment needs to concentrate on cleaning up its own act and concentrating on their…

ManagementPharmaceuticalPoliticsPolyplusSanofi

US FDA warns on over-prescribing of testosterone products

US FDA warns on over-prescribing of testosterone products

04-03-2015

The US Food and Drug Administration is requiring that the manufacturers of all approved prescription…

AbbVieAndroGelAxironEli LillyMen's HealthPharmaceuticalRegulationUSA

CASI Pharmaceuticals appoints Rong Chen as chief medical officer

CASI Pharmaceuticals appoints Rong Chen as chief medical officer

04-03-2015

Oncology biopharma company CASI Pharmaceuticals has appointed Rong Chen as chief medical officer.

BoardroomCASICASI PharmaceuticalsGlaxoSmithKlinePharmaceutical

Patent reform bill to protect innovation, confront abuse introduced in USA

Patent reform bill to protect innovation, confront abuse introduced in USA

04-03-2015

US Senators Chris Coons (Democrat, Delaware) and Dick Durbin (Democrat, Illinois), members of the Senate…

LegalPatentsPharmaceuticalPoliticsUSA

Takeda promotes Christophe Weber to chief executive

Takeda promotes Christophe Weber to chief executive

04-03-2015

Japan’s largest drugmaker Takeda Pharmaceutical has promoted Christophe Weber from representative director,…

BoardroomJapanPharmaceuticalTakeda PharmaTakeda Pharmaceutical

Orexigen shares jump on Contrave trial interim data but FDA orders more cardio studies

Orexigen shares jump on Contrave trial interim data but FDA orders more cardio studies

04-03-2015

The US Food and Drug Administration has said it is “disappointed” by Orexigen Therapeutics’ decision…

ContraveMetabolicsNeurologicalOrexigen TherapeuticsPharmaceuticalRegulationUSA

First launch for Eisai’s Lenvima, in the USA

First launch for Eisai’s Lenvima, in the USA

03-03-2015

The US subsidiary of Japanese pharma major Eisai has now launched its in-house developed novel anticancer…

EisailenvatinibLenvimaMarkets & MarketingOncologyPharmaceuticalRare diseases

Lilly licenses pomaglumetad methionil to Denovo as potential schizophrenia therapy

Lilly licenses pomaglumetad methionil to Denovo as potential schizophrenia therapy

03-03-2015

US drug major Eli Lilly has licensed late-stage neuroscience drug pomaglumetad methionil (mGlu2/3 receptor…

Eli LillyLicensingNeurologicalPharmaceuticalpomaglumetad methionilUSA

Blueprint Medicines in up to $265 million deal with Alexion

03-03-2015

Privately-held Blueprint Medicines has entered a strategic collaboration with USA-based Alexion Pharmaceuticals…

Alexion PharmaceuticalsBlueprint MedicinesLicensingPharmaceuticalRare diseases

Sun Pharma to buy GSK’s opiates business in Australia

Sun Pharma to buy GSK’s opiates business in Australia

03-03-2015

UK pharma major GlaxoSmithKline and India’s largest drugmaker by sales, Sun Pharmaceutical Industries,…

AustraliaGlaxoSmithKlineMergers & AcquisitionsNeurologicalPharmaceuticalSun Pharmaceutical Industries

FDA declines to expand approval of Pacira's Exparel for postsurgical analgesia

FDA declines to expand approval of Pacira's Exparel for postsurgical analgesia

03-03-2015

The US Food and Drug Administration has declined to expand the approval of Exparel (bupivacaine), manufactured…

AnalgesiaExparelPacira PharmaceuticalsPharmaceuticalRegulationUSA

Teva to sell Sellersville, PA, manufacturing facility to G&W Laboratories

Teva to sell Sellersville, PA, manufacturing facility to G&W Laboratories

03-03-2015

Israel-based Teva Pharmaceutical Industries is to sell its manufacturing facility in Sellersville, Pennsylvania,…

PharmaceuticalProductionTevaTeva Pharmaceutical IndustriesUSA

Endo to divest its American Medical Systems men's and prostate businesses to Boston Scientific

Endo to divest its American Medical Systems men's and prostate businesses to Boston Scientific

03-03-2015

Ireland-headquartered Endo International has entered into a definitive agreement with Boston Scientific…

EndoLicensingMen's HealthPharmaceuticalUSA

Merck KGaA 4th-quarter 2014 earnings beat expectations

Merck KGaA 4th-quarter 2014 earnings beat expectations

03-03-2015

Germany’s Merck KGaA this morning reported financial results showing that group sales for the full…

FinancialMerck KGaAMerck SeronoPharmaceutical

European Commission approves Actavis’ Xydalba

02-03-2015

The European Commission has granted Ireland-headquartered Actavis' subsidiary Durata Therapeutics International…

ActavisAngeliniAntibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsEuropePharmaceuticalXydalba

GSK and Novartis complete major three-part transaction

02-03-2015

UK pharma major GlaxoSmithKline said this morning that its three-part transaction with Swiss peer Novartis…

GlaxoSmithKlineMergers & AcquisitionsNovartisOncologyPharmaceuticalVaccines

China regulates hospital drug purchasing

02-03-2015

A document on hospital drug purchasing in China was released Saturday, which instructed that hospitals…

ChinaFinancialHealthcarePharmaceutical

Taiho Pharma Europe submits marketing application to EMA for TAS-102 in colorectal cancer

Taiho Pharma Europe submits marketing application to EMA for TAS-102 in colorectal cancer

02-03-2015

Taiho Pharma Europe, a subsidiary of Japanese pharma company Otsuka (TYO: 4768), has submitted a marketing…

EuropeOncologyPharmaceuticalRegulationTaiho PharmaceuticalsTAS-102

Global drugmakers slam restrictions on state tendering in Russia

02-03-2015

Leading global pharmaceutical producers operating in the Russian market have criticized a recent decision…

PharmaceuticalPricingRegulationRussia

South Korea pharma news briefs

02-03-2015

News items, as posted by the Korean Research-based Pharmaceutical Industry Association (KRPIA) last month,…

FinancialPharmaceuticalPricingRegulationSouth Korea

Novartis hit with 15-day suspension over omission of adverse events reporting

Novartis hit with 15-day suspension over omission of adverse events reporting

02-03-2015

Swiss drug major Novartis has been ordered to suspend operations in Japan for 15 days as of March 5,…

JapanLegalNovartisPharmaceuticalRegulation

1 to 25 of 7222 results

Back to top